Despite high expectations, productivity is frustratingly low in biopharmaceutical research and development. Although expenditures have increased, the number of new medicines resulting from human-genome sequencing has not. This means that a broad variety of diseases are not being treated effectively, in the developed or the developing worlds.
Advances in molecular sciences, corresponding to the sequencing of the human genome in the 1980s, led to the identification of all the human proteins — large, complex molecules necessary for many of the body’s functions. Understanding the proteins’ roles then led to greater knowledge of the underlying causes of diseases. For example, mutations, or defects, at specific molecular locations in human DNA were found to be responsible for some cancers, raising the hope of developing successful therapies tailored to individual patients.
Scientists believed that the ability to visualize and understand human biology at a more detailed level would lead to many new medicines. Identifying the defective molecular parts, known as the drug targets, should have made addressing the causes of disease easier, and would revolutionize the pharmaceutical sciences. And so it has — but without increasing the number of new medicines.
Prior to this molecular revolution, scientists discovered medicines by randomly evaluating different chemicals against phenotypes — an organism’s observable characteristics — in authentic biological systems, such as animals or cells. However, unfortunately, the phenotypic strategy is neither efficient nor intellectually satisfying.
The molecular revolution heralded an era in which drug discovery and development would be rational, not random. However, contrary to expectations, the increased efficiency implied by target identification has not increased productivity. Efforts to address the problem have focused on how the target was selected, the candidate drugs’ efficacy in humans, the risk of undesirable side effects and the efficiency of the discovery process — all to little or no avail.
The July issue of Nature Reviews Drug Discovery analyzed how first-in-class medicines — those drugs that successfully established a new class of medicines — were discovered. Despite the emphasis on target-based drug discovery, phenotypic screening produced the lion’s share of the first-in-class small-molecule medicines approved between 1999 and 2008 — 28 phenotypic medicines versus 17 target-based drugs. Considering how strongly biased the industry has been toward target-based drug discovery, that imbalance is highly significant.
The Nature Reviews article proposed that lower productivity partly reflects target-based discovery’s lack of consideration of the molecular complexities of how the drugs work. Knowing the parts of an efficient machine — a watch, an automobile or a computer — is not enough to describe how it works. The parts must collaborate in precise ways to provide accurate time, reliable transportation or processed information.
Biology is infinitely more complex. The phrase “molecular mechanism of action” (MMOA) describes the way that biological parts collaborate to provide an effective and safe medicine. Addressing the MMOA would contribute to reversing the low productivity of target-based discoveries, because merely knowing the identity of a part involved in a defect may not be sufficient to repair a malfunctioning machine.
The target-based approach is analogous to looking for one’s keys in the dark: If they are under a streetlight, they will be easy to find. Many hoped that the molecular revolution would amount to more streetlights for drug discovery. Unfortunately, it appears that this new light, in most cases, is too dim to illuminate the molecular details of the dynamic human biological machine with sufficient specificity to rationalize the design of new medicines.
The random phenotypic process, though less efficient, will ultimately identify medicines that are effective and work to repair disease. The target-based approach, on the other hand, creates only the illusion of greater efficiency; in reality, its promise has been undermined by its inattention to the MMOA.
There are too many molecular possibilities in dynamic human biology to identify a priori the optimal mechanism of molecular intervention. The way forward is to find a method that combines the efficiency of target-based approaches with the authenticity of phenotypic research.
David Swinney is at the Institute for Rare and Neglected Diseases Drug Discovery and was previously director of Virology Biochemical Pharmacology at Roche, Palo Alto, California.
Copyright: Project Syndicate
Late last month, Beijing introduced changes to school curricula in the Inner Mongolia Autonomous Region, requiring certain subjects to be taught in Mandarin rather than Mongolian. What is Chinese President Xi Jinping (習近平) seeking to gain from sending this message of pernicious intent? It is possible that he is attempting cultural genocide in Inner Mongolia, but does Xi also have the same plan for the democratic, independent nation of Mongolia? The controversy emerged with the announcement by the Inner Mongolia Education Bureau on Aug. 26 that first-grade elementary-school and junior-high students would in certain subjects start learning with Chinese-language textbooks, as
There are worrying signs that China is on the brink of a major food shortage, which might trigger a strategic contest over food security and push Chinese President Xi Jinping (習近平), already under intense pressure, toward drastic measures, potentially spelling trouble for Taiwan and the rest of the world. China has encountered a perfect storm of disasters this year. On top of disruption due to the COVID-19 pandemic, torrential rains have caused catastrophic flooding in the Yangtze River basin, China’s largest agricultural region. Floodwaters are estimated to have already destroyed the crops on 6 million hectares of farmland. The situation has been
In 1955, US general Benjamin Davis Jr, then-commander of the US’ 13th Air Force, drew a maritime demarcation line in the middle of the Taiwan Strait, known as the median line. Under pressure from the US, Taiwan and China entered into a tacit agreement not to cross the line. On July 9, 1999, then-president Lee Teng-hui (李登輝) described cross-strait relations as a “special state-to-state” relationship. In response, Beijing dispatched People’s Liberation Army (PLA) aircraft into the Taiwan Strait, crossing the median line for the first time since 1955. The PLA has begun to regularly traverse the line. On Sept. 18 and 19, it
On Sept. 8, at the high-profile Ketagalan security forum, President Tsai Ing-wen (蔡英文) urged countries to deal with the China challenge. She said: “It is time for like-minded countries, and democratic friends in the Indo-Pacific region and beyond, to discuss a framework to generate sustained and concerted efforts to maintain a strategic order that deters unilateral aggressive actions.” The “Taiwan model” to deal with the COVID-19 pandemic provides an alternative to China’s authoritarian way of handling it. Taiwan’s response to the health crisis has made it evident that countries across the world have much to learn from Taiwan’s best practices and if